McKesson to acquire controlling stake in Core Ventures for $2.49 billion in cash

McKesson said it hopes to “bring advanced treatments and improved care experiences to patients, while also reducing the overall cost of care.”

Previous post U.S. durable goods rise moderately in July — excluding volatile transportation sector
Next post SolarEdge’s stock surges as CEO steps down after 5 years in the role